2020 Analysis and Profile Directory of Contract Manufacturing Organizations in China's Biopharmaceutical Sector

News provided by

Sep 14, 2020, 09:45 ET

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- The "Growth of Biopharmaceutical Contract Manufacturing Organizations in China: An In-depth Study of Emerging Opportunities" report has been added to ResearchAndMarkets.com's offering.

This report on the China Contract Manufacturing Organizations (CMOs) industry covers regional industry developments, regulatory and legal changes, and reviews China's major CMO and CDMO companies with facility information, company ownership, background, management and facility capacity and history. This study is based on in-depth research, using public secondary and primary information resources.
This is an on-going project that will be updated in the future to provide trends information, and relevant new in-depth insights into the rapidly growing and changing Chinese biologics industry.

Highlights:

Top Ranked CDMO Facilities in China
Trends in the importance of Contract Manufacturing of biologics in China
How CMOs are meeting the increased demand and rapid capacity expansions
Analysis and Profile Directory of CMOs in China

Topline Findings:

China mAb Therapeutics expected to grow to USD $26 billion by 2030, with CMOs accessing an increasing share of domestic production.
Pipeline Growth in China is accelerating, including markets for mAb therapeutics and vaccines
Demand for biologics from domestic developers is increasing at 20% annually

Key Topics Covered:

Chapter 1: Introduction: Brief History Of China Biopharma Service Industry

Service and Business Model of a Biologics CMO
Business model of CDMOs
Biologics CDMOs Have High Barrier for Entry in China
Strong Growth Provides CMO Opportunities
History of China's Biologics CMOs and Policy Impacts

Chapter 2: Legal Framework of MAH, Government Subsidy Program And Implications

Introduction of MAH-related guidelines in Drug Administration Law (2019)
Current Status of MAH in China
Issues in MAH Implementation
Issues with Current Regulatory Framework
Government Subsidy Programs Related to MAH
Impact of MAH and Subsidy Programs on CDMOs

Chapter 3: Innovation in China Biopharma And Outsourcing of Commercial Scale Bioprocessing Domestic Developers Prefer In-house Manufacturing

Innovative Products More Likely Outsourced
Domestic Developers Progress in Innovation
Diversification Taking Place, but Pathway Remains Crowded
Biobetter vs. First-In-Class mAbs: A Major Trend
Company Pipelines and Capacity Needs for Chinese CMOs
Domestic CMO Capacity Needs in 5 Years
CMO Commercial Scale Bioprocessing Trends in China
CMO expanding capacity to reduce production costs
Chinese CMO Cost Reduction Efforts
More Commercial Scale CMO Bioprocessing Coming
Developers Becoming CMOs

Chapter 4: Who Uses China-Based Biologics CMOs

Using China-based CMOs for Western Markets
Case Studies
a. WuXi Biologics - TaiMed
b. WuXi Biologics - Shanghai Hile Biopharmaceutical
c. WuXi Biologics - Amicus
Overseas Clients Targeting China Markets
Case Studies
a. JHL Biotech - Sanofi
b. WuXi Biologics - AC Immune SA
Domestic CMO Clients Targeting Western
Case Studies
a. MabPlex - Encure Biopharma
b. WuXi Biologics - Ambrx - ZMC
Domestic Clients Targeting Domestic Markets
Case Studies
a. ShellBio - Lunan Pharma
b. Tobio Pharm - Zelgen Biopharma
How Domestic Clients Make Make vs. Buy' Decisions
Key Attributes in Selection of CMO

Chapter 5: China-Based Biologics CMOs

Idle Capacity Issue
Hiring Challenges Today
Summary of the China Biologics CMO Landscape
Categorization of China CMOs
Trends Among China Biologics CMOs
Overall Conclusion

Chapter 6: Domestic Biologics CMOs vs. MNC Biologics CDMOs

Strengths of Domestic Biologic CDMOs vs. MNC Biologics CDMOs
Weaknesses of China Biologics CDMOs vs. MNC Biologics CDMOs
Opportunities and Threats for China Biologics CDMOs
Strength, Weakness, and Threats of MNC CMOs
AppendIx I: Biopharmaceutical-Devoted CDMOs
AppendIx II: Companies With Biologics Development and CMO Operations
AppendIx III: Developer Companies Also CMOs

Companies Mentioned

3SBio
AlphaMab
Amoy-Top Biotech (subsidiary of Tonghua Dongbao)
Anhui Anke Biotechnology
Beigene
BeigeneJunshi Pharma/Jiangsu Suzhou
Benemae Pharmaceutical
Biotech Pharma
Boehringer-Ingelheim
CP Guojian Pharmaceutical
CSPC Pharma
Celgene Pharma/Shanghai
Changchun Hi-Tech #2 BCHT
Changchun Hi-Tech GeneScience
Changchun Institute
Chengdu Institute
Chia Tai Tianqing
Four Rings
GSK/Shenzhen
Gan & Lee
Generon
Genor
Henglius Pharma (a subsidiary of Fosun Pharma)
Hengrui Pharma/Lianyungang
Hengrui Pharma/Suzhou
Hisun
Huahai Pharma
Hualan/Beijing
Hualan/Xinxiang
Innovent Bio
JHL biotech
Jiangsu Wanbang
Junshi Pharma/Jiangsu, Suzhou
Junshi Pharma/Ligang, Shanghai
Kanghong Pharma
Kelun Pharma
Lanzhou Institute
Lee's Pharma
Livzon mAb
Luye Pharma
Mabtech holding Ltd
North China
Pfizer/Hangzhou
Qilu Pharma
SL Pharma/Beijing
SL Pharma/Quebec
Sanofi/Shenzhen
ShangPharma (Chempartner)
Shanghai Institute
Shanghai Pharma
Shanghai United Cell/Shanghai
Simcere Pharma/Jiangsu, Changzhou
Simcere Pharma/Yantai
SinoCellTech
Sinobioway/Tianjin
Sinovac/Beijing
Tasly
Teruisipharm
Tiantan Biologics
Tonghua DongBao
Tot Pharma
Tri-Prime Gene
Walvax/Kunming
Walvax/Taizhou
Walvax/Yuxi
Wuhan Institute
Wuxi Biologics
Yantai Rongchang (MABPLEX,subsidiary of Yantai Rongchang)
Zesun Pharma
Zhuhai Essex

For more information about this report visit https://www.researchandmarkets.com/r/jqu3pc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets